intermediate12 min read

Understanding Biotech Company Financials

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

Biotech investing can be thrilling, but it's also risky. Unlike most companies, many biotechs have no revenue—they're burning cash to develop drugs that may never make it to market. That's why understanding the financials is not just a nice-to-have; it's essential for survival. In this guide, you'll learn how to read a biotech's balance sheet and income statement like a pro. We'll break down cash runway, burn rate, and dilution risk—the three numbers that can make or break your investment. You'll also discover key metrics like R&D efficiency and how to spot red flags before they sink your portfolio. By the end, you'll be equipped to evaluate any pre-revenue biotech with confidence and avoid the common pitfalls that trip up retail investors.

1. The Lifeblood: Cash Runway

Cash runway is the amount of time a company can continue operating before it runs out of money. For a pre-revenue biotech, this is the single most important number. It's calculated by dividing the company's cash and cash equivalents by its monthly burn rate (the amount of cash it spends each month). For example, if a company has $100 million in cash and burns $10 million per month, its runway is 10 months. Why does this matter? Because if the company runs out of cash before it can get a drug approved or generate revenue, it will need to raise more money, often through dilutive financing. A runway of less than 12 months is a red flag, as it means the company will likely need to raise capital soon, potentially at a low stock price. Always check the cash runway in the most recent quarterly report (10-Q) or annual report (10-K).

Key takeaway

Cash runway tells you how long a biotech can survive without new funding. Aim for companies with at least 12 months of runway to avoid imminent dilution.

Example

In 2023, Sarepta Therapeutics had a cash runway of about 2 years, allowing it to weather delays in its gene therapy programs without immediate financing pressure.

2. The Burn Rate: How Fast Are They Spending?

Burn rate is the speed at which a company spends its cash. It's typically broken down into gross burn (total cash spent per month) and net burn (cash spent minus any cash received from operations, which for pre-revenue companies is usually just interest income). To calculate monthly burn, look at the cash flow statement in the company's financial filings. For example, if a company's cash balance decreased from $80 million to $50 million over a quarter, that's a $30 million quarterly burn, or $10 million per month. High burn rates aren't necessarily bad—they might indicate aggressive investment in promising clinical trials. But you need to compare the burn rate to the company's stage and pipeline. A company with a Phase 3 trial and a high burn rate might be justified, while a preclinical company with the same burn is a warning sign. Watch for trends: is the burn rate increasing faster than the pipeline's progress?

Key takeaway

Burn rate shows how quickly a company is using its cash. Compare it to the company's stage and pipeline to judge if spending is justified.

Example

Moderna's burn rate skyrocketed during the COVID-19 vaccine development, but it was justified by the potential revenue. In contrast, many small biotechs with high burn rates and early-stage pipelines have failed.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

3. Dilution Risk: The Hidden Tax on Shareholders

Dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For biotechs, this is a common way to raise cash, but it can be devastating if done at low prices. When a company announces a secondary offering, the stock often drops because investors know their shares will be worth less. To assess dilution risk, look at the company's share count and its history of offerings. Also check for 'at-the-market' (ATM) programs, which allow the company to sell shares gradually, and for warrants or convertible notes that could convert into shares. A high number of shares outstanding relative to the company's market cap can indicate heavy dilution. Always check the 'shares outstanding' and 'diluted shares' in the latest 10-Q. If a company has a history of frequent dilutive offerings, be cautious.

Key takeaway

Dilution reduces your stake in the company. Monitor share counts and watch for signs of frequent or large secondary offerings.

Example

In 2020, many small biotechs took advantage of high stock prices to raise cash, but those that did so at low prices, like some COVID-19 test developers, saw their stocks fall further as dilution compounded losses.

4. Key Financial Metrics: Beyond the Basics

While cash runway and burn rate are critical, other metrics provide deeper insight. R&D efficiency measures how much a company spends to advance its pipeline. You can calculate it by dividing R&D expenses by the number of clinical programs or by milestones achieved. A company that spends $500 million per Phase 3 trial might be inefficient compared to one that does it for $200 million. Another metric is 'cash per share,' which gives you a sense of how much cash backs each share. If a company has $10 per share in cash and no debt, it provides a floor for the stock price. Also look at 'debt'—biotechs often take on debt through convertible notes, which can be a double-edged sword. High debt increases financial risk, but convertible notes can be less dilutive if the stock price rises. Finally, check the 'current ratio' (current assets divided by current liabilities) to ensure the company can meet its short-term obligations.

Key takeaway

Look beyond cash and burn to metrics like R&D efficiency, cash per share, and debt to get a fuller picture of financial health.

Example

In 2021, a small biotech with $50 million in cash and a market cap of $100 million had a cash per share of $5, providing a cushion that attracted investors.

5. Red Flags in Biotech Financials

Certain financial patterns should raise immediate concerns. One red flag is a 'going concern' warning in the financial statements, indicating the company may not survive the year. Another is a history of repeated reverse stock splits, which are often used to maintain listing requirements but can signal financial distress. Watch for 'related-party transactions' where insiders are paying themselves excessive salaries or renting property to the company at above-market rates. Also be wary of companies that consistently miss their own guidance on cash runway or burn rate. Finally, if a company's cash burn is increasing while its pipeline is shrinking (e.g., after a failed trial), that's a sign of poor capital allocation. Always read the 'Liquidity and Capital Resources' section in the 10-K or 10-Q—it's where management discusses their financial strategy.

Key takeaway

Learn to spot red flags like going concern warnings, reverse splits, and insider deals. These can be early signs of trouble.

Example

In 2022, a biotech with a going concern warning saw its stock plummet after it announced it might not have enough cash to complete its Phase 2 trial.

Key terms

Cash Runway

The length of time a company can continue operating before it runs out of cash, calculated by dividing current cash by monthly burn rate.

Burn Rate

The rate at which a company spends its cash reserves, usually measured monthly. Gross burn is total cash spent; net burn is cash spent minus any cash received.

Dilution

The reduction in existing shareholders' ownership percentage caused by the issuance of new shares, often through secondary offerings or convertible securities.

Secondary Offering

A sale of new shares by a company to raise capital, which dilutes existing shareholders.

At-the-Market (ATM) Program

A mechanism that allows a company to sell shares gradually into the market at prevailing prices, providing flexible capital raising but with ongoing dilution.

Convertible Notes

Debt that can be converted into shares of the company's stock at a predetermined price, often used by biotechs to raise capital with lower interest rates.

R&D Efficiency

A measure of how effectively a company uses its research and development spending to advance its pipeline, often calculated as R&D expense per program or per milestone.

Cash per Share

A company's cash and cash equivalents divided by its shares outstanding, indicating the amount of cash backing each share.

Going Concern

An accounting term indicating that a company may not be able to continue operating for the next year, often due to insufficient cash or debt obligations.

Reverse Stock Split

A corporate action that reduces the number of shares outstanding while increasing the share price proportionally, often used to meet listing requirements but can signal financial distress.

Next steps

Pull up the latest 10-Q or 10-K for a biotech you're interested in and locate the cash flow statement. Calculate the monthly burn rate and cash runway.

Check the company's shares outstanding and any recent secondary offerings or ATM programs. Estimate potential dilution from outstanding warrants or convertible notes.

Review the 'Liquidity and Capital Resources' section in the management discussion to see if management discusses any financing plans or risks.

Compare the company's cash per share to its stock price. If the stock is trading below cash per share, it might be undervalued, but also consider the burn rate.

Set a rule for yourself: avoid biotechs with less than 12 months of cash runway unless you have a strong thesis for a near-term catalyst.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter published biotech profiles by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull and bear cases, and next expected data for every covered biotech.

Keep learning

Biotech Risk Management →How to Invest in Biotech Stocks →